πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

5,609 results for β€œAB” Clear

  1. Ondansetron

    United Therapeutics Europe Ltd

    IBS - Irritable Bowel Syndrome

    phase 3 small molecule completed

    1 trial

  2. Ondansetron Aurobindo 8 mg Filmtabletten, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Dexametazona Krka 4 mg comprimate, EMEND 125 mg+80 mg hard capsules, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer InfusionslΓΆsung, G

    Karyopharm Therapeutics Inc

    Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

    phase 3 small molecule active

    1 trial

  3. Ontamalimab

    Takeda

    Ulcerative Colitis

    phase 3 small molecule terminated

    3 trials

  4. Ontamalimab

    Shire

    Crohn's Disease

    phase 3 small molecule terminated

    1 trial

  5. Ontamalimab

    Takeda

    Crohn's Disease

    phase 3 mab terminated

    3 trials

  6. Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alpha (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks in Patients with Fabry Disease

    Chiesi Farmaceutici S.p.A

    Fabry disease (Ξ±-galactosidase A deficiency)

    phase 3 other active

    1 trial

  7. Open Label Topical Beremagene Geperpavec (B-VEC)

    Krystal Biotech Netherlands B.V.

    Dystrophic Epidermolysis Bullosa

    phase 3 mab completed

    1 trial

  8. Open-label pitolisant

    Harmony Biosciences Holdings

    Idiopathic Hypersomnia

    phase 3 small molecule completed

    1 trial

  9. Open-label rusfertide

    Protagonist Therapeutics, Inc

    Polycythemia Vera

    phase 3 small molecule active

    1 trial

  10. Opevesostat, FLUDROCORTISONE, PREDNISOLONE, DEXAMETHASONE ACETATE, HYDROCORTISONE, FLUDROCORTISONE ACETATE, ABIRATERONE ACETATE, DEXAMETHASONE, ABIRATERONE ACETATE, HYDROCORTISONE, HYDROCORTISONE, ENZALUTAMIDE, HYDROCORTISONE, PREDNISONE, PREDNISONE ACETATE, HYDROCORTISONE

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer

    phase 3 small molecule active

    1 trial

  11. Oral semaglutide

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  12. Oral treprostinil (UT-15C) sustained release tablets

    United Therapeutics Europe Ltd

    Pulmonary Hypertension

    phase 3 small molecule completed

    2 trials

  13. Orelabrutinib

    Zenas BioPharma

    Secondary Progressive Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  14. Orelabrutinib

    Zenas BioPharma

    Multiple Sclerosis (MS) Primary Progressive

    phase 3 small molecule active

    1 trial

  15. Orelabrutinib, Placebo tablets match with that of orelabrutinib (ICP-022) tablets in appearance, shape, size, and weight.

    Zenas BioPharma

    Primary Progressive Multiple Sclerosis (PPMS)

    phase 3 small molecule active

    1 trial

  16. Orforglipron

    Eli Lilly and Company

    Type 2 Diabetes

    phase 3 small molecule completed

    1 trial

  17. Orforglipron, Placebo to match LY, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron

    Eli Lilly Co.

    GZP1, GZP2: Obesity, Overweight GZP2: Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  18. Orodispersible tablet, BUL03, Jorveza 1 mg orodispersible tablets

    Dr. Falk Pharma GmbH

    eosinophilic esophagitis

    phase 3 small molecule active

    1 trial

  19. Otezla 10mg, 20mg, 30 mg film-coated tablets, Matching Placebo for TAK-279 Dose A, ZASOCITINIB, ZASOCITINIB, Matching Placebo for TAK-279 Dose B, Otezla 10mg, 20mg, 30 mg film-coated tablets, Matching Placebo for Apremilast, Otezla 10mg, 20mg, 30 mg film-coated tablets

    Takeda

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  20. Otezla 10mg, 20mg, 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets, Apremilast placebo (same excipient as over-encapsulated Otezla), Otezla 10mg, 20mg, 30 mg film-coated tablets, ZASOCITINIB, Otezla 30 mg film-coated tablets, TAK-279 placebo (same excipient as TAK-279)

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  21. Otezla 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets, TAK-279 placebo (same excipient as TAK-279), Otezla 10mg, 20mg, 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets, Apremilast placebo (same excipient as over-encapsulated Otezla), ZASOCITINIB

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  22. Ozempic 1 mg solution for injection in pre-filled pen, Semaglutide placebo, solution for injection in 1.5 mL pre-filled PDS290 pen injector

    NovoThirteen

    While it is well-established that long-term good glycaemic control will reduce the risk of diabetic retinopathy development and progression, intensification of glycaemic control has also been associated with an initial worsening of diabetic retinopathy. This phenomenon is known as β€œearly worsening”. The rationale of this trial is to establish the long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (T2D) using validated and standardised ophthalmic assessments. This trial is a post-authorisation safety study (PASS) conducted as a commitment to the European Medicines Agency

    phase 3 small molecule active

    1 trial

  23. PACLITAXEL , BNT327, PEMETREXED , CARBOPLATIN , BNT327, PEMBROLIZUMAB

    BioNTech SE

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  24. PACLITAXEL , GEMCITABINE , CARBOPLATIN , BNT327, Abraxane 5 mg/ml powder for dispersion for infusion., ERIBULIN , BNT327 Placebo

    BioNTech SE

    First line triple-negative breast cancer (TNBC)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources